Alliance and Collaboration (Details) € in Millions, $ in Millions									1 Months Ended	3 Months Ended		6 Months Ended			7 Months Ended	12 Months Ended
	Mar. 29, 2024 USD ($)	Feb. 26, 2024 USD ($)	Feb. 23, 2024 USD ($)	Feb. 23, 2024 EUR (€)	Jan. 24, 2024	Oct. 12, 2023 product	Dec. 28, 2022	May 07, 2018 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 EUR (€)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Feb. 23, 2024 EUR (€)	Dec. 05, 2023 USD ($)
License Agreement with Orion Corporation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term							8 years
Collaborative arrangement renew for successive term							2 years
Collaborative arrangement license revenue agreement										$ 0.7	$ 0.0	$ 1.3		$ 0.6
License Agreement with Orion Corporation | Accounts Payable and Accrued Liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred income									$ 7.8	9.0		9.0			$ 9.0	$ 7.8
License Agreement with Orion Corporation | Other long-term liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred income									4.7	$ 2.2		2.2			2.2	4.7
ONGENTYS® License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, medical and marketing activities																			$ 6.0
Collaborative arrangement, medical and marketing activities expense															$ 3.5
Collaborative arrangement non-refundable license fee									$ 12.5
Collaborative arrangement non-refundable license fee, amortization period									8 years
License supply agreement, potential future milestone payments									$ 22.5
Knight Therapeutics International S.A. License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term					15 years
Collaborative arrangement renew for successive term					2 years
License supply agreement, potential future milestone payments		$ 10.5
Notice period					1 year
Nonrefundable license fee received, amount		$ 1.0
License Agreement with Zambon Biotech
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term			15 years	15 years
Collaborative arrangement renew for successive term			2 years	2 years
License supply agreement, potential future milestone payments			$ 76.6	€ 71.5
Notice period			1 year	1 year
Nonrefundable license fee received, amount			$ 5.4															€ 5.0
Collaborative arrangement net revenue agreement												3.5	€ 3.2
Biosimilar Licensing and Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments																66.0
Other long term liabilities								$ 78.3
Collaborative arrangement maximum milestone paid																2.5	$ 26.5
Estimated useful life (in years)																	7 years
Collaborative arrangement aggregate sales-based milestone payment	$ 9.5
Collaborative arrangement, number of products | product						2
Collaborative arrangement upfront payment												$ 3.0				2.5
Biosimilar Licensing and Supply Agreement | Development Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments																3.5
Biosimilar Licensing and Supply Agreement | Regulatory Approval
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments																$ 15.0
Biosimilar Licensing and Supply Agreement | Achievement of Cumulative Net Sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments														$ 47.5